A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2018
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Cervical cancer
- Focus Diagnostic use
- Sponsors Navidea Biopharmaceuticals
- 16 Apr 2018 Status changed from recruiting to discontinued.
- 21 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2018.
- 21 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2018.